Poseida Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 330
- Market Cap
- $272.9M
- Website
- http://www.poseida.com
- Introduction
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT)
FDA grants RMAT designation to Poseida Therapeutics' P-BCMA-ALLO1, an allogeneic CAR-T therapy for relapsed/refractory multiple myeloma, based on positive Phase 1 study data.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath